ArticleERJ open research2022
Chronic cough in Germany: results from a general-population survey.
Article in ERJ open research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Quality of life associated with chronic cough in the multinational Burden of Obstructive Lung Disease study: a cross-sectional study.ERJ open research · 2025Article
- Prevalence and burden of possible refractory chronic cough in four European countries.ERJ open research · 2025Article
- Prevalence and burden of chronic cough in China: results from a population-based survey.BMC pulmonary medicine · 2025Article
- The prevalence and risk factors of respiratory symptoms in Finland: a comparative analysis.European clinical respiratory journal · 2025Article
- Cross-sectional evaluation of patients with refractory or unexplained chronic cough by office-based pulmonologists in Germany.Frontiers in medicine · 2025Article
- Prevalence, clinical characteristics, and disease burden of chronic cough in Italy: a cross-sectional study.BMC pulmonary medicine · 2024Article
- Prevalence and burden of chronic cough in France.ERJ open research · 2024Article
- Prevalence of chronic cough, its risk factors and population attributable risk in the Burden of Obstructive Lung Disease (BOLD) study: a multinational cross-sectional study.EClinicalMedicine · 2024Article
- Burden of refractory and unexplained chronic cough on patients' lives: a cohort study.ERJ open research · 2023Article
- Potential Saving of Antibiotics for Respiratory Infections in Several European Countries: Insights from Market Research Data.Antibiotics (Basel, Switzerland) · 2023Article
- Article
- Health-Related Quality of Life and Its Determinants in Chronic Cough: The Korean Chronic Cough Registry Study.Allergy, asthma & immunology research · 2023Article
- Worldwide prevalence, risk factors and burden of chronic cough in the general population: a narrative review.Journal of thoracic disease · 2023Review
- Impact of high-risk of obstructive sleep apnea on chronic cough: data from the Korea National Health and Nutrition Examination Survey.BMC pulmonary medicine · 2022Article
- A retrospective study to understand the journey and health status of patients with unexplained or refractory chronic cough in the Netherlands.Chronic respiratory diseaseObservational
- Basic assessment of chronic cough in primary care and referral pathways of patients to different specialists.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic cough (CC) which is defined ≥8 weeks is a common condition in clinical practice. However, estimates of prevalence and associated comorbidities in German adults and key subgroups of age and gender are lacking.
methodsCross-sectional study based on a representative panel of 15 020 adult subjects of the general population who completed the German National Health and Wellness Survey, reporting CC and questions about comorbidities. Lifetime and 12-month prevalence are presented as unweighted estimates.
resultsThe lifetime CC prevalence was 6.5% (range across age groups 5.1%-8.3%) and the 12-month prevalence was 4.9% (range 3.7-5.7%). The prevalence of diagnosed CC was 2.8% (range 0.9-4.1%) and the prevalence of persons currently on any prescription to treat CC was 0.6% (range 0.2-1.4%). Respondents who experienced CC were 52.0±17.0 years old, with a higher prevalence in those aged 50 years and older. Persons with CC had higher morbidity scores and were diagnosed with an increased number of comorbidities, most frequently diagnoses of the respiratory system (71.0%), followed by digestive tract disorders (34.0%) and sleep disorders (37.6%).
conclusionsIn a broadly representative sample of German adults, lifetime and 12-month prevalence of CC was greatest in current and former smokers and those older ≥50 years of age. Comorbidities are frequent and may complicate management of these patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.